Thu Aug 28 09:00:53 SGT 2014  
    Genital Warts Treatment, Timor-Leste
HIV STD TESTING SINGAPORE™
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

Genital Warts Treatment, Timor-Leste | HIV STD TESTING SINGAPORE™

Summary

Genital Warts Treatment, Timor-Leste | HIV STD TESTING SINGAPORE™ @beautytimorleste_com: Genital warts (condyloma, condylomata acuminata, venereal wart, anal wart, anogenital wart, "cauliflower" sex disease) symptoms in men/women, screening/diagnosis, testing/check, treatment clinic, Timor-Leste - Private and confidential service. Definitions, references, and latest news.

Keywords: Genital Warts Treatment Timor-Leste, Timor-Leste Genital Warts Treatment, Genital Warts Treatment.

Description

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital Warts Treatment, Timor-Leste
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Anal human papillomavirus infection prevalence in men who have sex with men is age-independent: a role for recent sexual behavior?
Tue, 26 Aug 2014 11:21:33 +0100 | Future Microbiology
Future Microbiology July 2014, Vol. 9, No. 7, Pages 837-844. (Source: Future Microbiology)

An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters
Mon, 25 Aug 2014 00:00:00 +0100 | American Journal of Epidemiology
We present this model in response to a call for new natural history models of cervical cancer intended for decision analysis and economic evaluation at a time when global cervical cancer prevention policy continues to evolve and evidence of the long-term health effects of cervical interventions remains critical. (Source: American Journal of Epidemiology)

Meta‐analysis of type‐specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination
Mon, 25 Aug 2014 00:00:00 +0100 | Journal of Medical Virology
In conclusion, this meta‐analysis highlights the necessity of introducing vaccination program in Iran. J. Med. Virol. © 2014 Wiley Periodicals, Inc. (Source: Journal of Medical Virology)

A 4-month-old baby presenting with dermal necrotizing granulomatous giant cell reaction at the injection site of 13-valent pneumococcal conjugate vaccine: a case report
Sun, 24 Aug 2014 00:00:00 +0100 | Epidemiologic Perspectives and Innovations
Conclusions:

HPV catch-up vaccination of young women: a systematic review and meta-analysis
Sat, 23 Aug 2014 00:00:00 +0100 | BMC Public Health - Latest articles
Conclusions:

New York Council Speaker Says Biopsy Shows She Doesn’t Have Cancer
Fri, 22 Aug 2014 19:35:50 +0100 | NYT Health
Melissa Mark-Viverito made her announcement days after revealing she has human papillomavirus, an infection linked to cervical cancer. (Source: NYT Health)

Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
Fri, 22 Aug 2014 04:00:00 +0100 | EurekAlert! - Infectious and Emerging Diseases
(Somers Media) Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by Hera Therapeutics Inc. combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer.When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to the NIH-funded research of Louise T. Chow, Ph.D. and Thomas Broker, Ph.D. (Source: EurekAlert! - Infectious and Emerging Diseases)

Low prevalence of human papillomavirus in head and neck squamous cell carcinoma in Chinese patients
Fri, 22 Aug 2014 00:00:00 +0100 | Journal of Medical Virology
The aim of this study was to ascertain the prevalence and prognostic value of human papillomavirus (HPV) infection status in head and neck squamous cell carcinoma. Immunohistochemistry and GenoArray HPV genotyping assays were used to evaluate the HPV infection status of 256 Chinese patients with head and neck squamous cell carcinoma. Long‐term survival rates were calculated using the Kaplan–Meier method. Immunostaining for p16 was prevalent in 6.6% (17/256) of patients, whereas HPV infection was detected in 9 of 256 (3.5%) patients using the HPV genotyping test. None of the p16‐negative subjects were found to have HPV infection according to the HPV genotyping test. P16 positivity was more common among nonsmokers than smokers (16.3% vs. 4.7%, respectively; P = 0.02). Among nine HP...

Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer
Thu, 21 Aug 2014 00:00:00 +0100 | Journal of Translational Medicine
Conclusions:

The HPV vaccine: beating cervical cancer – questions and answers
Thu, 21 Aug 2014 00:00:00 +0100 | NHS Networks
The FAQ addresses questions about the human papillomavirus vaccine to protect girls against cervical cancer. (Source: NHS Networks)